Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses
Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses on the complete response (CR) data from 269 evaluable patients who received tositumomab/iodine-131 tositumomab in phase I-III trials from 1990 to 1999.
A total of 42% of patients had received one to three prior chemotherapies and 33% of patients had received four prior chemotherapies. Baseline characteristics were as follows: 70% less than 60 years old, 56% male, 89% stage III or IV at protocol entry, 46% positive bone marrow involvement at study entry, and 32% bulky disease (> 500 g).
Patients received tositumomab/iodine-131 tositumomab as previously described (Blood 90:1259, 2000; J Clin Oncol 18:1316, 2000). A total of 88 patients (33%) had a CR; 74 (28%) had a confirmed CR (two assessments 4 weeks apart). The median follow-up was 1.5 years (range: 1 day to 8 years). The median duration of CR was 3.25 years, and that for confirmed CR was 5 years. The table below displays the subgroups that were significantly different (P < .05) via univariate analyses:
CONCLUSION: These results demonstrate that tositumomab/iodine-131 tositumomab produces a high CR rate in patients with low-grade or transformed low-grade NHL, and that these CRs are durable.
Click here to read Dr. Bruce Cheson's commentary on this abstract.
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.